Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Share-based Compensation (2019 - 2025)

Korro Bio (KRRO) has disclosed Share-based Compensation for 6 consecutive years, with $1.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Share-based Compensation rose 43.36% year-over-year to $1.8 million, compared with a TTM value of $6.9 million through Sep 2025, up 284.26%, and an annual FY2024 reading of $4.5 million, up 87.4% over the prior year.
  • Share-based Compensation was $1.8 million for Q3 2025 at Korro Bio, down from $2.0 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $6.1 million in Q2 2021 and bottomed at -$14.3 million in Q4 2022.
  • Average Share-based Compensation over 5 years is $1.4 million, with a median of $1.8 million recorded in 2025.
  • The sharpest move saw Share-based Compensation crashed 376.63% in 2022, then surged 215.1% in 2024.
  • Year by year, Share-based Compensation stood at $5.2 million in 2021, then plummeted by 376.63% to -$14.3 million in 2022, then skyrocketed by 51.89% to -$6.9 million in 2023, then soared by 119.75% to $1.4 million in 2024, then surged by 34.49% to $1.8 million in 2025.
  • Business Quant data shows Share-based Compensation for KRRO at $1.8 million in Q3 2025, $2.0 million in Q2 2025, and $1.8 million in Q1 2025.